<DOC>
	<DOCNO>NCT01839552</DOCNO>
	<brief_summary>Lazanda prescription nasal spray medicine contain medicine fentanyl . It use manage breakthrough pain adult cancer already routinely take opioid pain medicine around-the-clock cancer pain . Lazanda start take opioid pain medicine patient 's body become use ( opioid tolerant ) . The purpose study assess ability Lazanda control pain episode breakthrough pain cancer patient .</brief_summary>
	<brief_title>An Assessment Ability Fentanyl Citrate Nasal Spray Manage Breakthrough Pain Cancer Patients .</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Patients meet follow criterion eligible : 1 . At least 18 year age old . 2 . Diagnosed cancer . 3 . Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . 4 . Patients cancer experience episode BTPc spite optimize background analgesia least 60 mg/day morphine ( equivalent analgesic ) least 7 day . 5 . Patients cancer currently use SAO ( short act opioid ) manage episodes BTPc . 6 . Patients cancer fail obtain timely response , determine Principal Investigator , pain SAO therapy . 7 . Laboratory value consistent stage disease deem clinically insignificant investigator . 8 . Female patient child bear potential male patient partner child bear potential use adequate form contraception study entry , agree use adequate form contraception additional month study . Adequate contraception define use hormonal contraception intrauterine device female patient/partner plus use least 1 partner additional spermicidecontaining barrier method contraception . The use barrier method alone abstinence consider adequate . 9 . Willing able give write informed consent participate study . Patients meet follow criterion exclude study : 1 . Patients opioid tolerant . 2 . Patients know intolerance hypersensitivity fentanyl . 3 . Physical abnormality nose could affect nasal absorption . 4 . Patients uncontrolled rapidly escalate pain . 5 . Patients history alcohol substance abuse . 6 . A clinically significant medical history ( past present ) disease would compromise study wellbeing patient . 7 . Patients participate another clinical trial analgesic within last month . 8 . Patients previously use FCNS adequate response . 9 . Female patient positive pregnancy test currently lactate . 10 . Patients take medication know inhibitor CYP3A4 isoenzyme , ketoconazole . 11 . Patients take monoamine oxidase inhibitor within 14 day dose study medication . 12 . Patients unsuitable inclusion reason , opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Fentanyl Citrate Nasal Spray ( FCNS )</keyword>
	<keyword>Lazanda</keyword>
	<keyword>Breakthrough pain cancer patient</keyword>
</DOC>